norfloxacin has been researched along with Bacterial Disease in 214 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to evaluate the role of prophylactic norfloxacin in preventing bacterial infections and its effect on transplant-free survival (TFS) in patients with acute-on-chronic liver failure (ACLF) identified by the Asian Pacific Association for the Study of the Liver criteria." | 9.51 | Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial. ( Fatima, S; Gora, BA; Gujjarlapudi, D; Gupta, R; Kulkarni, AV; Kumar, K; Premkumar, M; Rao, PN; Rapole, B; Reddy, DN; Sasikala, M; Sharma, M; Simhadri, V; Tirumalle, S; Yelamanchili, S, 2022) |
| "Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites." | 9.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "Two hundred and sixty two cirrhotic patients with ascites and a previous episode of SBP were assigned randomly to receive either 1200 mg rifaximin or 400 mg of norfloxacin daily for 6 months." | 9.22 | Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, A; Ibrahim, S; Soliman, S, 2016) |
| "Selective intestinal decontamination with norfloxacin is useful in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding." | 9.08 | Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding. ( Balanzó, J; Guarner, C; Kolle, L; Novella, MT; Ortiz, J; Pamplona, J; Sàbat, M; Sainz, S; Soriano, G; Torras, J; Villanueva, C, 1998) |
| "The effect of a combination regimen using norfloxacin (NFLX) and amphotericin B (AMPH-B) for prevention of infections in patients with acute leukemia being treated by remission-induction chemotherapy in a randomized, controlled trial was studied." | 9.07 | Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. ( Dan, K; Nomura, T; Yamada, T, 1993) |
| "To assess the efficacy of selective intestinal decontamination with norfloxacin in the prevention of bacterial infections in cirrhotic patients with gastrointestinal hemorrhage, 119 patients were included in a prospective randomized study." | 9.07 | Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. ( Anguera, A; Balanzó, J; Cussó, X; González, D; Guarner, C; Sainz, S; Soriano, G; Tomás, A; Torras, X; Villanueva, C, 1992) |
| "In this double-masked study, we randomly assigned 488 patients with clinical signs of acute bacterial conjunctivitis or blepharitis, or both, to treatment with either norfloxacin ophthalmic solution 0." | 9.07 | Topically administered norfloxacin compared with topically administered gentamicin for the treatment of external ocular bacterial infections. The Worldwide Norfloxacin Ophthalmic Study Group. ( Cook, TJ; Miller, IM; Vogel, R; Wittreich, J, 1992) |
| "Seventy-three patients mainly receiving consolidation therapy for acute leukemia or autologous bone marrow transplantation were studied in a randomized trial comparing nystatin with norfloxacin (800 mg) given orally QID, for prevention of infection." | 9.07 | [A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study]. ( Hattori, M; Maseki, N; Sampi, K, 1992) |
| "Eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis were included in a multicenter, double-blind trial aimed at comparing long-term norfloxacin administration (400 mg/day; 40 patients) vs." | 9.06 | Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. ( Almela, M; Forné, M; Ginés, P; Llach, J; Marco, F; Miranda, ML; Planas, R; Rimola, A; Salmerón, JM; Vargas, V, 1990) |
| "The efficacy and safety of Norfloxacin were studied in the treatment of 20 patients with acute epididymitis." | 9.06 | [Clinical study of norfloxacin in the treatment of acute epididymitis]. ( Arakawa, S; Fujii, A; Ka, S; Kamidono, S; Kawabata, G; Maeda, H; Matsumoto, O; Morishita, S; Takagi, S; Umezu, K, 1989) |
| "A double-blind controlled trial of norfloxacin versus cotrimoxazole in the treatment of urinary tract infections was conducted." | 9.06 | A double-blind controlled trial of norfloxacin versus cotrimoxazole in the treatment of urinary tract infections. ( Chan, MK; Cheng, IK; Wong, WT, 1989) |
| "The efficacy and safety of norfloxacin were compared with those of placebo, vancomycin-polymyxin, and trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of bacterial infections in granulocytopenic patients." | 9.06 | Norfloxacin for prevention of bacterial infections in granulocytopenic patients. ( Bartlett, J; Champlin, RE; Deresinski, S; Finley, RS; Ho, WG; Joshi, JH; Karp, J; Levitt, L; Talbot, G; Winston, DJ, 1987) |
| "The study compared the efficacy and safety of norfloxacin to those of co-trimoxazole in the treatment of urinary tract infections (UTI)." | 9.06 | Treatment of urinary tract infections in Hong Kong: a comparative study of norfloxacin and co-trimoxazole. ( Chan, MK; Cheng, IK; Li, MK; Wong, WS; Wong, WT; Yin, PD, 1988) |
| "The clinical and bacteriological efficacy of norfloxacin and co-trimoxazole was compared in patients with symptomatic upper urinary tract infections (UTI)." | 9.06 | Norfloxacin versus co-trimoxazole for the treatment of upper urinary tract infections: a double blind trial. ( Chongthaleong, A; Petcharabutr, OA; Sitprija, V; Tungsanga, K; Udomsantisuk, N; Wong, EC, 1988) |
| "A total of 63 neutropenic patients receiving cytotoxic therapy for acute leukemia were randomly allocated to receive norfloxacin (400 mg every 12 hours) or cotrimoxazole (160/800 mg every 12 hours) to prevent bacterial infection." | 9.06 | Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. ( Bow, EJ; Louie, TJ; Rayner, E, 1988) |
| "Respiratory tract infections were treated with pefloxacin in fifteen patients, who were hospitalized in the intensive care unit and required artificial ventilation." | 9.06 | Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit. ( Boland, DM; de Jong, D; MacLaren, DM; van Gestel, WC, 1987) |
| "We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bacterial infections in 68 adult patients who had acute leukemia throughout prolonged courses of granulocytopenia (median, 32 days)." | 9.06 | Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1987) |
| "For recipients who have received prophylactic norfloxacin, clinicians should be aware of the high risk of multidrug-resistant bacterial infections during the first month after liver transplant." | 8.31 | Impact of Prophylactic Norfloxacin in Multidrug Resistant Bacterial Infections in the Early Liver Posttransplant Period. ( Castells, L; Dopazo, C; Len, O; Lladó, L; Los-Arcos, I; Lung, M; Nuvials, X; Oriol, I; Pérez-Cameo, C; Sabé, N, 2023) |
| "Although norfloxacin (N) is widely accepted as the drug of choice for spontaneous bacterial peritonitis (SBP) prophylaxis, there is data to suggest that trimethoprim-sulfamethoxazole (TS) may be similarly effective." | 7.74 | Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis. ( Angus, PW; Gow, PJ; Lontos, S; Vaughan, RB, 2008) |
| "The extensive use of invasive procedures and of long-term norfloxacin prophylaxis in the management of cirrhotic patients may have influenced the epidemiology of bacterial infections in cirrhosis." | 7.71 | Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. ( Arroyo, V; Colmenero, J; Fernández, J; Gómez, J; Navasa, M; Rodés, J; Vila, J, 2002) |
| "The therapeutic effectiveness of a single oral dose (60 and 200 mg/kg body weight) of fosfomycin trometamol (FT), norfloxacin, trimethoprim sulfamethoxazole (Bactrim) and pipemidic acid against experimental cystitis in the rat were compared." | 7.67 | Treatment of experimental cystitis in the rat with a single dose of fosfomycin trometamol. ( Dubini, F; Riviera, L, 1988) |
| "Norfloxacin (NFLX), a new quinolone antibacterial agent, was investigated for its antibacterial activity and clinical efficacy on respiratory tract infections." | 7.67 | [Laboratory and clinical studies of norfloxacin in respiratory tract infections]. ( Fujiue, Y; Ikeda, M; Jyo, T; Kodomari, Y; Kuwabara, M; Muroki, K; Yamakido, M, 1988) |
| " There was no difference among the studied groups regarding the incidence and severity of adverse events reported." | 6.82 | Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. ( Abdelaziz, A; Abdelrashed, M; Assem, M; El-Azab, G; Elemam, S; Elsabaawy, M; Hamed, W; Khodeer, S, 2016) |
| "Both norfloxacin and TMP/SMX were clinically effective in the treatment of travelers' diarrhea in this military population." | 6.67 | Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa. ( Batchelor, RA; Bourgeois, AL; Burr, DH; Gardiner, C; Garst, P; Hyams, KC; Kilpatrick, ME; Oprandy, JJ; Thornton, SA; Wignall, SF, 1992) |
| "Norfloxacin was not superior to other antibiotics." | 6.66 | Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. ( Fernandez, J; Ferstl, PG; Graf, C; Herrmann, E; Lange, CM; Mücke, MM; Mücke, VT; Schwarzkopf, KM; Trebicka, J; Zeuzem, S, 2020) |
| "Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group." | 6.66 | Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. ( Ameglio, F; Casali, A; Frasca, AM; Gallo Curcio, C; Modugno, G; Paoletti, G; Tonachella, R; Tropea, F; Verri, C, 1988) |
| "Aerobic gram negative bacterial infections occur commonly in patients with acute leukemia undergoing intensive chemotherapy-induced bone marrow aplasia, and often arise from the gastrointestinal (GI) tract." | 6.66 | Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1986) |
| "This study aimed to evaluate the role of prophylactic norfloxacin in preventing bacterial infections and its effect on transplant-free survival (TFS) in patients with acute-on-chronic liver failure (ACLF) identified by the Asian Pacific Association for the Study of the Liver criteria." | 5.51 | Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial. ( Fatima, S; Gora, BA; Gujjarlapudi, D; Gupta, R; Kulkarni, AV; Kumar, K; Premkumar, M; Rao, PN; Rapole, B; Reddy, DN; Sasikala, M; Sharma, M; Simhadri, V; Tirumalle, S; Yelamanchili, S, 2022) |
| "These studies reported a 1-year recurrence rate of 20-26%." | 5.51 | Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin. ( Barcán, LA; Bermudez, C; Diaz, JM; Dirchwolf, M; Gadano, AC; Giunta, D; Gutierrez-Acevedo, MN; Marciano, S; Smud, A, 2019) |
| "The 1-year recurrence rate of SBP can be as high as 30-70%." | 5.30 | An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. ( Ganiats, TG; McHutchison, JG; Younossi, ZM, 1997) |
| "Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites." | 5.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "Two hundred and sixty two cirrhotic patients with ascites and a previous episode of SBP were assigned randomly to receive either 1200 mg rifaximin or 400 mg of norfloxacin daily for 6 months." | 5.22 | Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, A; Ibrahim, S; Soliman, S, 2016) |
| "Oral norfloxacin is the standard of therapy in the prophylaxis of bacterial infections in cirrhotic patients with gastrointestinal hemorrhage." | 5.12 | Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. ( Arroyo, V; Durandez, R; Fernández, J; Gómez, C; Guarner, C; Navasa, M; Planas, R; Ruiz del Arbol, L; Serradilla, R, 2006) |
| "The efficacy of the prophylactic administration of sulfamethoxazole/trimethoprim (ST) plus norfloxacin (NFLX) versus ST alone to prevent the development of bacterial infection during chemotherapy-induced leukopenia was compared in patients with lung cancer." | 5.08 | A randomized controlled trial of sulfamethoxazole/trimethoprim plus norfloxacin versus sulfamethoxazole/trimethoprim alone for the prophylaxis of bacteria infection during chemotherapy for lung cancer. ( Kunikane, H; Kunitoh, H; Nagatomo, A; Okamoto, H; Watanabe, K, 1998) |
| "Selective intestinal decontamination with norfloxacin is useful in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding." | 5.08 | Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding. ( Balanzó, J; Guarner, C; Kolle, L; Novella, MT; Ortiz, J; Pamplona, J; Sàbat, M; Sainz, S; Soriano, G; Torras, J; Villanueva, C, 1998) |
| "The effect of a combination regimen using norfloxacin (NFLX) and amphotericin B (AMPH-B) for prevention of infections in patients with acute leukemia being treated by remission-induction chemotherapy in a randomized, controlled trial was studied." | 5.07 | Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. ( Dan, K; Nomura, T; Yamada, T, 1993) |
| "To assess the efficacy of selective intestinal decontamination with norfloxacin in the prevention of bacterial infections in cirrhotic patients with gastrointestinal hemorrhage, 119 patients were included in a prospective randomized study." | 5.07 | Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. ( Anguera, A; Balanzó, J; Cussó, X; González, D; Guarner, C; Sainz, S; Soriano, G; Tomás, A; Torras, X; Villanueva, C, 1992) |
| "In this double-masked study, we randomly assigned 488 patients with clinical signs of acute bacterial conjunctivitis or blepharitis, or both, to treatment with either norfloxacin ophthalmic solution 0." | 5.07 | Topically administered norfloxacin compared with topically administered gentamicin for the treatment of external ocular bacterial infections. The Worldwide Norfloxacin Ophthalmic Study Group. ( Cook, TJ; Miller, IM; Vogel, R; Wittreich, J, 1992) |
| "Seventy-three patients mainly receiving consolidation therapy for acute leukemia or autologous bone marrow transplantation were studied in a randomized trial comparing nystatin with norfloxacin (800 mg) given orally QID, for prevention of infection." | 5.07 | [A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study]. ( Hattori, M; Maseki, N; Sampi, K, 1992) |
| "More patients receiving ciprofloxacin did not develop fever during neutropenia and did not receive antibiotics (34%) compared with those receiving norfloxacin (25%) (P = 0." | 5.07 | Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. ( , 1991) |
| "Eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis were included in a multicenter, double-blind trial aimed at comparing long-term norfloxacin administration (400 mg/day; 40 patients) vs." | 5.06 | Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. ( Almela, M; Forné, M; Ginés, P; Llach, J; Marco, F; Miranda, ML; Planas, R; Rimola, A; Salmerón, JM; Vargas, V, 1990) |
| "The efficacy and safety of Norfloxacin were studied in the treatment of 20 patients with acute epididymitis." | 5.06 | [Clinical study of norfloxacin in the treatment of acute epididymitis]. ( Arakawa, S; Fujii, A; Ka, S; Kamidono, S; Kawabata, G; Maeda, H; Matsumoto, O; Morishita, S; Takagi, S; Umezu, K, 1989) |
| "A double-blind controlled trial of norfloxacin versus cotrimoxazole in the treatment of urinary tract infections was conducted." | 5.06 | A double-blind controlled trial of norfloxacin versus cotrimoxazole in the treatment of urinary tract infections. ( Chan, MK; Cheng, IK; Wong, WT, 1989) |
| "The efficacy and safety of norfloxacin were compared with those of placebo, vancomycin-polymyxin, and trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis of bacterial infections in granulocytopenic patients." | 5.06 | Norfloxacin for prevention of bacterial infections in granulocytopenic patients. ( Bartlett, J; Champlin, RE; Deresinski, S; Finley, RS; Ho, WG; Joshi, JH; Karp, J; Levitt, L; Talbot, G; Winston, DJ, 1987) |
| "The study compared the efficacy and safety of norfloxacin to those of co-trimoxazole in the treatment of urinary tract infections (UTI)." | 5.06 | Treatment of urinary tract infections in Hong Kong: a comparative study of norfloxacin and co-trimoxazole. ( Chan, MK; Cheng, IK; Li, MK; Wong, WS; Wong, WT; Yin, PD, 1988) |
| "The clinical and bacteriological efficacy of norfloxacin and co-trimoxazole was compared in patients with symptomatic upper urinary tract infections (UTI)." | 5.06 | Norfloxacin versus co-trimoxazole for the treatment of upper urinary tract infections: a double blind trial. ( Chongthaleong, A; Petcharabutr, OA; Sitprija, V; Tungsanga, K; Udomsantisuk, N; Wong, EC, 1988) |
| "A total of 63 neutropenic patients receiving cytotoxic therapy for acute leukemia were randomly allocated to receive norfloxacin (400 mg every 12 hours) or cotrimoxazole (160/800 mg every 12 hours) to prevent bacterial infection." | 5.06 | Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. ( Bow, EJ; Louie, TJ; Rayner, E, 1988) |
| "Respiratory tract infections were treated with pefloxacin in fifteen patients, who were hospitalized in the intensive care unit and required artificial ventilation." | 5.06 | Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit. ( Boland, DM; de Jong, D; MacLaren, DM; van Gestel, WC, 1987) |
| "We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bacterial infections in 68 adult patients who had acute leukemia throughout prolonged courses of granulocytopenia (median, 32 days)." | 5.06 | Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1987) |
| "The use of norfloxacin either as primary or secondary prophylaxis of bacterial infections in advanced cirrhosis has improved patient's survival." | 4.91 | Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis. ( Francés, R; González-Navajas, JM; Such, J; Zapater, P, 2015) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| "The clinical and bacteriological activity of fosfomycin trometamol (FT) has been compared with several other antibiotics in the treatment of uncomplicated urinary tract infections." | 4.82 | Short term therapy for uncomplicated urinary tract infection today. Clinical outcome upholds the theories. ( Lobel, B, 2003) |
| "For recipients who have received prophylactic norfloxacin, clinicians should be aware of the high risk of multidrug-resistant bacterial infections during the first month after liver transplant." | 4.31 | Impact of Prophylactic Norfloxacin in Multidrug Resistant Bacterial Infections in the Early Liver Posttransplant Period. ( Castells, L; Dopazo, C; Len, O; Lladó, L; Los-Arcos, I; Lung, M; Nuvials, X; Oriol, I; Pérez-Cameo, C; Sabé, N, 2023) |
| "Norfloxacin administration is useful in preventing bacterial infections in cirrhosis but associated to the generation of resistant species." | 3.88 | Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. ( Bellot, P; Francés, R; García, I; Gimenez, P; Gómez-Hurtado, I; González-Navajas, JM; Guarner, F; Manichanh, C; Ramos, JM; Such, J; Zapater, P, 2018) |
| "Consecutively admitted patients with cirrhosis and ascitic fluid (AF) with: spontaneous bacterial peritonitis (SBP), non-infected AF, and norfloxacin as secondary SBP prophylaxis (SID group)." | 3.83 | Selective intestinal decontamination with norfloxacin enhances a regulatory T cell-mediated inflammatory control mechanism in cirrhosis. ( Caparrós, E; Francés, R; Giménez, P; Gómez-Hurtado, I; González-Navajas, JM; Juanola, O; Moratalla, A; Piñero, P; Such, J; Zapater, P, 2016) |
| "or t." | 3.76 | World-wide clinical experience with norfloxacin: efficacy and safety. ( Corrado, M; Hoagland, V; Sabbaj, J; Wang, C, 1986) |
| "Although norfloxacin (N) is widely accepted as the drug of choice for spontaneous bacterial peritonitis (SBP) prophylaxis, there is data to suggest that trimethoprim-sulfamethoxazole (TS) may be similarly effective." | 3.74 | Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis. ( Angus, PW; Gow, PJ; Lontos, S; Vaughan, RB, 2008) |
| " The bactDNA translocation was investigated in 226 patients with cirrhosis and noninfected ascites, 22 patients with spontaneous bacterial peritonitis, and 10 patients with ascites receiving continuous norfloxacin." | 3.74 | Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. ( Bellot, P; Caño, R; Francés, R; González-Navajas, JM; Moreu, R; Muñoz, C; Pascual, S; Pérez-Mateo, M; Such, J; Zapater, P, 2008) |
| "The extensive use of invasive procedures and of long-term norfloxacin prophylaxis in the management of cirrhotic patients may have influenced the epidemiology of bacterial infections in cirrhosis." | 3.71 | Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. ( Arroyo, V; Colmenero, J; Fernández, J; Gómez, J; Navasa, M; Rodés, J; Vila, J, 2002) |
| "At the Eastern Section Meeting of the Triological Society January 26, 1990, Levinson et al reported outstanding success with ciprofloxacin in the treatment of malignant otitis externa." | 3.68 | The fluoroquinolones. ( Brody, T; Pensak, ML, 1991) |
| "Systemic bacterial infections due to Escherichia coli MB 2884, Proteus mirabilis MB 3125 and Klebsiella pneumoniae MB 4005 were well controlled by treatment with norfloxacin both in normal and streptozotocin-induced diabetic mice." | 3.67 | Antibacterial efficacy of norfloxacin, trimethoprim-sulfamethoxazole, and gentamicin in experimentally-infected normal and streptozotocin-induced diabetic mice. ( Abruzzo, GK; Fromtling, RA; Gadebusch, HH, 1984) |
| "To prevent bacterial infections in the neutropenic post-transplant period, norfloxacin 400mg twice daily was administered as oral prophylaxis to 44 marrow recipients isolated in laminar airflow rooms (LAFRs)." | 3.67 | Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation. ( Aversa, F; Bucaneve, G; Del Favero, A; Felicini, R; Greco, M; Martelli, MF; Menichetti, F; Moretti, MV; Pasquarella, C, 1989) |
| "Selective antimicrobial decontamination with norfloxacin was compared with vancomycin/polymyxin for prophylaxis of bacterial infections in granulocytopenic patients." | 3.67 | Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. ( Champlin, RE; Gale, RP; Ho, WG; Nakao, SL; Winston, DJ, 1986) |
| " We have previously demonstrated that the ability to suppress bacterial colonization of this site with oral norfloxacin prophylaxis (400 mg every 12 h) affects the incidence and distribution of aerobic gram-negative bacterial infections and the overall management of infectious complications in this patient population." | 3.67 | Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient. ( Dick, JD; Karp, JE; Merz, WG, 1988) |
| "The therapeutic effectiveness of a single oral dose (60 and 200 mg/kg body weight) of fosfomycin trometamol (FT), norfloxacin, trimethoprim sulfamethoxazole (Bactrim) and pipemidic acid against experimental cystitis in the rat were compared." | 3.67 | Treatment of experimental cystitis in the rat with a single dose of fosfomycin trometamol. ( Dubini, F; Riviera, L, 1988) |
| "Norfloxacin (NFLX), a new quinolone antibacterial agent, was investigated for its antibacterial activity and clinical efficacy on respiratory tract infections." | 3.67 | [Laboratory and clinical studies of norfloxacin in respiratory tract infections]. ( Fujiue, Y; Ikeda, M; Jyo, T; Kodomari, Y; Kuwabara, M; Muroki, K; Yamakido, M, 1988) |
| "Sixteen patients, 14 with an infection of the lower respiratory tract and two with cholangitis, were treated with pefloxacin 400 mg bid or tid." | 3.67 | Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units. ( Lauwers, S; Naessens, A; Pierard, D; Vincken, W, 1986) |
| "Following a summary of the main bacteriological and pharmacokinetic properties of this new quinolone derivative, the author reviews the results obtained with pefloxacine in the treatment of urinary tract infection, gonococcal urethritis, and bronchopulmonary, surgical, gynaecological, bone, soft tissue, neuromeningeal and ENT infections." | 3.67 | [Pefloxacin: evaluation and clinical prospects]. ( Modaï, J, 1986) |
| " There was no difference among the studied groups regarding the incidence and severity of adverse events reported." | 2.82 | Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. ( Abdelaziz, A; Abdelrashed, M; Assem, M; El-Azab, G; Elemam, S; Elsabaawy, M; Hamed, W; Khodeer, S, 2016) |
| "Due to a high number of bacterial infections antibiotics administration has been indicated in these patients." | 2.71 | [Factors participating in development of bleeding varices in portal hypertension. Part I: bacterial infection and comparison of intravenous and peroral antibiotics effects--a randomised study]. ( Dastych, M; Díte, P; Husová, L; Juránková, J; Lata, J; Príbramská, V; Senkyrík, M, 2004) |
| "To determine the prevalence of bacterial infection in patients admitted to hospital with variceal bleeding in comparison with patients with liver cirrhosis admitted because of another reason." | 2.71 | Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics--a randomized trial. ( Dastych, M; Díte, P; Husová, L; Juránková, J; Kroupa, R; Lata, J; Príbramská, V; Senkyrík, M, 2005) |
| "Norfloxacin treatment was associated with a persistent decrease in gram-negative isolates (p < 0." | 2.68 | Use of norfloxacin for prevention of symptomatic urinary tract infection in chronically catheterized patients. ( Rutschmann, OT; Zwahlen, A, 1995) |
| "Both norfloxacin and TMP/SMX were clinically effective in the treatment of travelers' diarrhea in this military population." | 2.67 | Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa. ( Batchelor, RA; Bourgeois, AL; Burr, DH; Gardiner, C; Garst, P; Hyams, KC; Kilpatrick, ME; Oprandy, JJ; Thornton, SA; Wignall, SF, 1992) |
| "Norfloxacin was not superior to other antibiotics." | 2.66 | Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. ( Fernandez, J; Ferstl, PG; Graf, C; Herrmann, E; Lange, CM; Mücke, MM; Mücke, VT; Schwarzkopf, KM; Trebicka, J; Zeuzem, S, 2020) |
| "Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group." | 2.66 | Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. ( Ameglio, F; Casali, A; Frasca, AM; Gallo Curcio, C; Modugno, G; Paoletti, G; Tonachella, R; Tropea, F; Verri, C, 1988) |
| "Norfloxacin has been compared to placebo (136 patients), sulfamethoxazole plus trimethoprim (SXT, 72 patients) and oral vancomycin plus colistin (V/C, 61 patients) for the prevention of alimentary tract-associated infections during and after induction chemotherapy." | 2.66 | The tolerability profile of prophylactic norfloxacin in neutropenic patients. ( Corrado, ML; Hesney, M; Struble, WE, 1988) |
| "Aerobic gram negative bacterial infections occur commonly in patients with acute leukemia undergoing intensive chemotherapy-induced bone marrow aplasia, and often arise from the gastrointestinal (GI) tract." | 2.66 | Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1986) |
| "Hospital-acquired and community-acquired bacterial infections have already put a heavy burden on the global health system." | 2.61 | Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. ( Zhang, B, 2019) |
| "Bacterial infections are common in cirrhotic patients with acute variceal bleeding, occurring in 20% within 48 h." | 2.50 | Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding. ( Lee, YY; Mahadeva, S; Tee, HP, 2014) |
| " They are well absorbed after oral administration, and some achieve serum and tissue levels well exceeding the minimal inhibitory concentrations for susceptible bacteria." | 2.37 | Symposium on antimicrobial agents. The quinolones. ( Walker, RC; Wright, AJ, 1987) |
| "Norfloxacin has great potential for the treatment of bacterial enteric infections reflected by its broad in vitro activity as well as its effectiveness in initial clinical trials." | 2.37 | Norfloxacin in the treatment of bacterial enteric infections. ( Ruiz-Palacios, GM, 1986) |
| "Norfloxacin has a well proven efficacy in UTI but remains to be proven in enteric infections." | 2.37 | Principles for targeted antibiotic use in urinary tract and enteric infections: a review with special emphasis on norfloxacin. ( Norrby, SR, 1986) |
| " It is difficult to generalize their clinical usefulness, since these agents exhibit different pharmacokinetic profiles, antimicrobial activity (with varied minimum inhibitory concentrations among similar organisms), and dosage regimens." | 2.37 | Review of the 4-quinolones. ( Eggleston, M; Park, SY, 1987) |
| "These studies reported a 1-year recurrence rate of 20-26%." | 1.51 | Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin. ( Barcán, LA; Bermudez, C; Diaz, JM; Dirchwolf, M; Gadano, AC; Giunta, D; Gutierrez-Acevedo, MN; Marciano, S; Smud, A, 2019) |
| "The norfloxacin release was found to be swelling controlled initially and diffusion controlled at the extended release periods." | 1.32 | Norfloxacin-loaded chitosan sponges as wound dressing material. ( Agalar, C; Denkbaş, EB; Keçeci, K; Ozdemir, N; Oztürk, E, 2004) |
| "The 1-year recurrence rate of SBP can be as high as 30-70%." | 1.30 | An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. ( Ganiats, TG; McHutchison, JG; Younossi, ZM, 1997) |
| " We employed a rat model of chronic bacterial prostatitis to investigate any pharmacokinetic differences that may exist between uninflamed and inflamed prostate glands." | 1.29 | Antibiotic pharmacokinetics in the inflamed prostate. ( Ceri, H; Clark, J; Downey, J; Nickel, JC; Olson, M, 1995) |
| "Fifty-one patients with localized prostate cancer were prostatectomized and followed up after a mean observation time of 73 months." | 1.29 | Transrectal ultrasound and core biopsies for the diagnosis of prostate cancer. A study of pretreatment investigation strategy for patients with suspected prostate cancer. ( Norberg, M, 1994) |
| "This study analyzes hospital acquired bacterial infections in cirrhotic patients with ascites and low levels of total protein in ascitic fluid (n = 53) and cirrhotic patients with gastrointestinal hemorrhage (n = 26), both submitted to selective intestinal decontamination with norfloxacin during the hospitalization." | 1.28 | [An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination]. ( Balanzó, J; Fábrega, E; Guarner, C; Méndez, C; Soriano, G; Such, J; Teixidó, M; Tena, F; Tomás, A; Villanueva, C, 1991) |
| " A dose-response relationship was observed between doses/body weight and peak serum concentrations." | 1.28 | [Basic and clinical studies on norfloxacin in the pediatric field]. ( Iwai, N; Kasai, K; Katayama, M; Miyazu, M; Nakamura, H, 1990) |
| " NFLX was given to patients according to a dosing regimen with 4." | 1.28 | [Laboratory and clinical studies on norfloxacin in the pediatric field]. ( Fukushima, Y; Imai, H; Koizumi, M; Sakaguchi, N; Sugita, M; Toyonaga, Y; Yamasaki, M, 1990) |
| "Amikacin was tested against the same bacteria except Streptococcus faecalis." | 1.28 | Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo. ( Renneberg, J; Walder, M, 1989) |
| "Norfloxacin was least active against Clostridium difficile (90% minimal inhibitory concentration, 128 micrograms/ml)." | 1.27 | In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. ( Gadebusch, HH; Shungu, DL; Weinberg, E, 1983) |
| "Norfloxacin was the most active agent in the study on a weight-for-weight basis." | 1.27 | Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens. ( Dibb, WL; Digranes, A; Ostervold, B, 1984) |
| "Ciprofloxacin was 2-8 fold more active than norfloxacin and 100-fold more active than nalidixic acid." | 1.27 | The in vitro and in vivo activity of ciprofloxacin. ( Grohe, K; Zeiler, HJ, 1984) |
| "Ciprofloxacin was the most active quinolone tested against both gentamicin-susceptible and gentamicin-resistant stains, having an MIC90 equal or less than 1 mg/l for all species studied." | 1.27 | The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients. ( Guimaraes, MA; Noone, P, 1986) |
| "Infections with anaerobes, as well as bacterial infections of the respiratory tract were, however, not prevented." | 1.27 | Infections after experimental cadaver bone marrow transplantation in beagle dogs. Transplantations with and without selective gastrointestinal decontamination. ( Haralambie, E; Schmidt-Weinmar, A, 1988) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| "Norfloxacin treatment resulted in clinical cure or improvement in 84 percent of patients and eradicated the etiologic pathogen(s) 52 percent of the time." | 1.27 | Compassionate use of norfloxacin. ( Corrado, ML; Heseltine, PN, 1987) |
| "Ofloxacin is a new quinolone carboxylic acid compound." | 1.27 | In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents. ( Kumada, T; Neu, HC, 1985) |
| "Pefloxacin was given as the single drug (except in one case) to twenty-seven patients with a variety of infections (bone and/or joint: 8; respiratory tract: 6; urinary tract: 5; bacteremia: 4; meninges: 3; other: 1)." | 1.27 | [Pefloxacin: clinical experience]. ( Bertrand, A; Janbon, F; Jonquet, O; Jourdan, J; Santoni, A, 1985) |
| "Norfloxacin is a quinolinecarboxylic acid compound." | 1.26 | In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. ( Labthavikul, P; Neu, HC, 1982) |
| " The dose-response curve of AM-715 indicated a steep gradient, and the 50% inhibited doses of AM-715 were 0." | 1.26 | In vitro antibacterial activity of AM-715, a new nalidixic acid analog. ( Hirai, K; Inoue, M; Irikura, T; Ito, A; Koga, H; Mitsuhashi, S; Suzue, S, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 98 (45.79) | 18.7374 |
| 1990's | 55 (25.70) | 18.2507 |
| 2000's | 24 (11.21) | 29.6817 |
| 2010's | 32 (14.95) | 24.3611 |
| 2020's | 5 (2.34) | 2.80 |
| Authors | Studies |
|---|---|
| McGuirk, PR | 1 |
| Jefson, MR | 1 |
| Mann, DD | 1 |
| Elliott, NC | 1 |
| Chang, P | 1 |
| Cisek, EP | 1 |
| Cornell, CP | 1 |
| Gootz, TD | 1 |
| Haskell, SL | 1 |
| Hindahl, MS | 1 |
| Sanchez, JP | 2 |
| Bridges, AJ | 2 |
| Bucsh, R | 1 |
| Domagala, JM | 2 |
| Gogliotti, RD | 1 |
| Hagen, SE | 2 |
| Heifetz, CL | 1 |
| Joannides, ET | 1 |
| Sesnie, JC | 1 |
| Shapiro, MA | 1 |
| Culbertson, TP | 1 |
| Gambino, L | 1 |
| Karrick, G | 1 |
| Porter, K | 1 |
| Sesnie, JA | 1 |
| Spense, FG | 1 |
| Chu, DT | 3 |
| Fernandes, PB | 3 |
| Maleczka, RE | 2 |
| Nordeen, CW | 2 |
| Pernet, AG | 2 |
| Claiborne, AK | 1 |
| Pihuleac, E | 1 |
| Miller, AA | 1 |
| Bundy, GL | 1 |
| Mott, JE | 1 |
| Skepner, JE | 1 |
| Boyle, TP | 1 |
| Harris, DW | 1 |
| Hromockyj, AE | 1 |
| Marotti, KR | 1 |
| Zurenko, GE | 1 |
| Munzner, JB | 1 |
| Sweeney, MT | 1 |
| Bammert, GF | 1 |
| Hamel, JC | 1 |
| Ford, CW | 1 |
| Zhong, WZ | 1 |
| Graber, DR | 1 |
| Martin, GE | 1 |
| Han, F | 1 |
| Dolak, LA | 1 |
| Seest, EP | 1 |
| Ruble, JC | 1 |
| Kamilar, GM | 1 |
| Palmer, JR | 1 |
| Banitt, LS | 1 |
| Hurd, AR | 1 |
| Barbachyn, MR | 1 |
| Gadakh, AV | 1 |
| Pandit, C | 1 |
| Rindhe, SS | 1 |
| Karale, BK | 1 |
| Liu, XF | 1 |
| Zheng, CJ | 1 |
| Sun, LP | 1 |
| Liu, XK | 1 |
| Piao, HR | 1 |
| Shelke, SN | 1 |
| Mhaske, GR | 1 |
| Bonifácio, VD | 1 |
| Gawande, MB | 1 |
| Srivastava, N | 1 |
| Kumar, A | 2 |
| Shi, LP | 1 |
| Jiang, KM | 1 |
| Jiang, JJ | 1 |
| Jin, Y | 1 |
| Tao, YH | 1 |
| Li, K | 1 |
| Wang, XH | 1 |
| Lin, J | 1 |
| Yin, BT | 1 |
| Yan, CY | 1 |
| Peng, XM | 2 |
| Zhang, SL | 1 |
| Rasheed, S | 1 |
| Geng, RX | 2 |
| Zhou, CH | 2 |
| Karad, SC | 1 |
| Purohit, VB | 1 |
| Thakor, P | 1 |
| Thakkar, VR | 1 |
| Raval, DK | 1 |
| Jeyakkumar, P | 1 |
| Liu, HB | 1 |
| Gopala, L | 1 |
| Cheng, Y | 1 |
| Zha, GF | 1 |
| Wang, SM | 1 |
| Rakesh, KP | 1 |
| Bukhari, SNA | 1 |
| Manukumar, HM | 1 |
| Vivek, HK | 1 |
| Mallesha, N | 1 |
| Qin, HL | 1 |
| Zhang, B | 1 |
| Zhang, J | 5 |
| Ba, Y | 1 |
| Wang, S | 1 |
| Yang, H | 1 |
| Hou, X | 1 |
| Xu, Z | 1 |
| Kulkarni, AV | 1 |
| Tirumalle, S | 1 |
| Premkumar, M | 1 |
| Kumar, K | 1 |
| Fatima, S | 1 |
| Rapole, B | 1 |
| Simhadri, V | 1 |
| Gora, BA | 1 |
| Sasikala, M | 1 |
| Gujjarlapudi, D | 1 |
| Yelamanchili, S | 1 |
| Sharma, M | 1 |
| Gupta, R | 1 |
| Rao, PN | 1 |
| Reddy, DN | 1 |
| Jiang, Y | 3 |
| Fang, S | 3 |
| Feng, J | 3 |
| Ruan, Q | 3 |
| Marciano, S | 2 |
| Gutierrez-Acevedo, MN | 2 |
| Barbero, S | 1 |
| Del C Notari, L | 1 |
| Agozino, M | 1 |
| Fernandez, JL | 1 |
| Anders, MM | 1 |
| Grigera, N | 1 |
| Antinucci, F | 1 |
| Orozco Ganem, OF | 1 |
| Murga, MD | 1 |
| Perez, D | 1 |
| Palazzo, A | 1 |
| Martinez Rejtman, L | 1 |
| Duarte, IG | 1 |
| Vorobioff, J | 1 |
| Trevizan, V | 1 |
| Bulaty, S | 1 |
| Bessone, F | 1 |
| Valverde, M | 1 |
| Elizondo, M | 1 |
| Bosia, JD | 1 |
| Borzi, SM | 1 |
| Stieben, TE | 1 |
| Masola, A | 1 |
| Ferretti, SE | 1 |
| Arufe, D | 1 |
| Demirdjian, E | 1 |
| Raffa, MP | 1 |
| Peralta, M | 1 |
| Fainboim, HA | 1 |
| Vazquez, CE | 1 |
| Ruiz, P | 1 |
| Martínez, JE | 1 |
| Heffner, LA | 1 |
| Odzak, A | 1 |
| Dirchwolf, M | 2 |
| Smud, A | 2 |
| Mendizabal, M | 1 |
| Bellizzi, C | 1 |
| Martinez, A | 1 |
| Tomatis, J | 1 |
| Bruno, A | 1 |
| Ramos, A | 2 |
| Pages, J | 1 |
| Tevez, S | 1 |
| Gadano, AC | 2 |
| Giunta, DH | 1 |
| Pérez-Cameo, C | 1 |
| Oriol, I | 1 |
| Lung, M | 1 |
| Lladó, L | 1 |
| Dopazo, C | 1 |
| Nuvials, X | 1 |
| Los-Arcos, I | 1 |
| Sabé, N | 1 |
| Castells, L | 1 |
| Len, O | 2 |
| Mücke, MM | 1 |
| Mücke, VT | 1 |
| Graf, C | 1 |
| Schwarzkopf, KM | 1 |
| Ferstl, PG | 1 |
| Fernandez, J | 4 |
| Zeuzem, S | 1 |
| Trebicka, J | 1 |
| Lange, CM | 1 |
| Herrmann, E | 1 |
| Dave, V | 1 |
| Kushwaha, K | 1 |
| Yadav, RB | 1 |
| Agrawal, U | 1 |
| Gómez-Hurtado, I | 3 |
| Gimenez, P | 3 |
| García, I | 1 |
| Zapater, P | 7 |
| Francés, R | 7 |
| González-Navajas, JM | 6 |
| Manichanh, C | 1 |
| Ramos, JM | 1 |
| Bellot, P | 4 |
| Guarner, F | 1 |
| Such, J | 9 |
| Yim, HJ | 1 |
| Suh, SJ | 1 |
| Jung, YK | 1 |
| Yim, SY | 1 |
| Seo, YS | 1 |
| Lee, YR | 1 |
| Park, SY | 2 |
| Jang, JY | 1 |
| Kim, YS | 1 |
| Kim, HS | 1 |
| Kim, BI | 1 |
| Um, SH | 1 |
| Menshawy, A | 1 |
| Mattar, O | 1 |
| Barssoum, K | 1 |
| AboEl-Naga, AM | 1 |
| Salim, HM | 1 |
| Mohamed, AMF | 1 |
| Elgebaly, A | 1 |
| Abd-Elsalam, S | 2 |
| Diaz, JM | 1 |
| Bermudez, C | 1 |
| Barcán, LA | 1 |
| Giunta, D | 1 |
| Facciorusso, A | 1 |
| Papagiouvanni, I | 1 |
| Cela, M | 1 |
| Buccino, VR | 1 |
| Sacco, R | 1 |
| Wang, W | 2 |
| Yang, J | 1 |
| Liu, C | 1 |
| Song, P | 1 |
| Xu, H | 1 |
| Xia, X | 1 |
| Molla, R | 1 |
| Tiruneh, M | 1 |
| Abebe, W | 1 |
| Moges, F | 1 |
| Lee, YY | 1 |
| Tee, HP | 1 |
| Mahadeva, S | 1 |
| Lontos, S | 2 |
| Shelton, E | 1 |
| Angus, PW | 2 |
| Vaughan, R | 1 |
| Roberts, SK | 1 |
| Gordon, A | 1 |
| Gow, PJ | 2 |
| Garcia-Martinez, I | 1 |
| Moratalla, A | 2 |
| Lozano-Ruiz, B | 1 |
| Mostafa, T | 1 |
| Badra, G | 1 |
| Abdallah, M | 1 |
| Assem, M | 1 |
| Elsabaawy, M | 1 |
| Abdelrashed, M | 1 |
| Elemam, S | 1 |
| Khodeer, S | 1 |
| Hamed, W | 1 |
| Abdelaziz, A | 1 |
| El-Azab, G | 1 |
| Juanola, O | 1 |
| Caparrós, E | 1 |
| Piñero, P | 1 |
| Elfert, A | 1 |
| Abo Ali, L | 1 |
| Soliman, S | 1 |
| Ibrahim, S | 1 |
| Caño, R | 3 |
| Llanos, L | 1 |
| Ruiz-Alcaraz, AJ | 1 |
| Pascual, S | 3 |
| Barquero, C | 1 |
| Moreu, R | 2 |
| Horga, JF | 1 |
| Muñoz, C | 3 |
| Pérez, J | 1 |
| García-Peñarrubia, P | 1 |
| Pérez-Mateo, M | 3 |
| Zhang, S | 1 |
| Zhang, W | 1 |
| Wang, Y | 2 |
| Jin, Z | 1 |
| Wang, X | 2 |
| Zhang, Y | 1 |
| San-Juan, R | 1 |
| Aguado, JM | 1 |
| Lumbreras, C | 1 |
| Fortun, J | 1 |
| Munoz, P | 1 |
| Montejo, M | 1 |
| Moreno, A | 1 |
| Cordero, E | 1 |
| Blanes, M | 1 |
| Torre-Cisneros, J | 1 |
| López-Medrano, F | 1 |
| Carratala, J | 1 |
| Moreno, E | 1 |
| Pande, C | 1 |
| Sarin, SK | 1 |
| Zhu, L | 1 |
| Dong, Z | 1 |
| Xie, S | 1 |
| Chen, X | 1 |
| Lu, M | 1 |
| Li, X | 1 |
| Zhou, W | 1 |
| Karakan, T | 1 |
| Tahtaci, M | 1 |
| Alagozlu, H | 1 |
| Barisić, Z | 1 |
| Babić-Erceg, A | 1 |
| Borzić, E | 1 |
| Zoranić, V | 1 |
| Kaliterna, V | 1 |
| Carev, M | 1 |
| Lobel, B | 1 |
| Roseeuw, E | 1 |
| Coessens, V | 1 |
| Balazuc, AM | 1 |
| Lagranderie, M | 1 |
| Chavarot, P | 1 |
| Pessina, A | 1 |
| Neri, MG | 1 |
| Schacht, E | 1 |
| Marchal, G | 1 |
| Domurado, D | 1 |
| Denkbaş, EB | 1 |
| Oztürk, E | 1 |
| Ozdemir, N | 1 |
| Keçeci, K | 1 |
| Agalar, C | 1 |
| Lata, J | 2 |
| Juránková, J | 2 |
| Husová, L | 2 |
| Senkyrík, M | 2 |
| Díte, P | 2 |
| Dastych, M | 2 |
| Príbramská, V | 2 |
| Soza, A | 1 |
| Riquelme, A | 1 |
| González, R | 1 |
| Alvarez, M | 1 |
| Pérez-Ayuso, RM | 1 |
| Glasinovic, JC | 1 |
| Arrese, M | 1 |
| Kroupa, R | 1 |
| Giuliano, M | 1 |
| Gentile, G | 1 |
| Pantosti, A | 1 |
| Micozzi, A | 2 |
| Arcese, W | 1 |
| Martino, P | 2 |
| Bassily, S | 1 |
| Mikhail, I | 1 |
| Haberberger, RL | 1 |
| Zakaria, S | 1 |
| Yassa, M | 1 |
| El Masry, NA | 1 |
| Woody, JN | 1 |
| Cristiano, P | 1 |
| Peppas, T | 1 |
| Petrikkos, G | 1 |
| Deliganni, V | 1 |
| Zoumboulis, P | 1 |
| Koulentianos, E | 1 |
| Giamarellou, H | 1 |
| Itha, S | 1 |
| Sharma, A | 1 |
| Bhatt, G | 1 |
| Ruiz del Arbol, L | 1 |
| Gómez, C | 1 |
| Durandez, R | 1 |
| Serradilla, R | 1 |
| Guarner, C | 6 |
| Planas, R | 2 |
| Arroyo, V | 3 |
| Navasa, M | 3 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Márquez, D | 1 |
| Santana, F | 1 |
| Vaughan, RB | 1 |
| Newsom, SW | 1 |
| Matthews, J | 1 |
| Amphlett, M | 1 |
| Warren, RE | 1 |
| Neu, HC | 3 |
| Labthavikul, P | 1 |
| Shungu, DL | 1 |
| Weinberg, E | 1 |
| Gadebusch, HH | 2 |
| Rylander, M | 1 |
| Norrby, SR | 2 |
| Bailey, RR | 2 |
| Peddie, BA | 1 |
| Blake, E | 1 |
| Chartrand, SA | 1 |
| Scribner, RK | 1 |
| Weber, AH | 1 |
| Welch, DF | 1 |
| Marks, MI | 1 |
| Nakamura, S | 2 |
| Nakata, K | 2 |
| Katae, H | 1 |
| Minami, A | 2 |
| Kashimoto, S | 2 |
| Yamagishi, J | 1 |
| Takase, Y | 1 |
| Shimizu, M | 1 |
| Kouno, K | 2 |
| Inoue, M | 4 |
| Mitsuhashi, S | 5 |
| Digranes, A | 1 |
| Dibb, WL | 1 |
| Ostervold, B | 1 |
| Zeiler, HJ | 1 |
| Grohe, K | 1 |
| Bauernfeind, A | 1 |
| Ullmann, U | 1 |
| Fromtling, RA | 1 |
| Abruzzo, GK | 1 |
| Ito, A | 2 |
| Hirai, K | 4 |
| Koga, H | 1 |
| Suzue, S | 3 |
| Irikura, T | 3 |
| Abe, Y | 1 |
| Rutschmann, OT | 1 |
| Zwahlen, A | 1 |
| Schölmerich, J | 2 |
| Gerbes, AL | 1 |
| Andus, T | 1 |
| Leser, HG | 1 |
| Nickel, JC | 1 |
| Downey, J | 1 |
| Clark, J | 1 |
| Ceri, H | 1 |
| Olson, M | 1 |
| Wilcox, MH | 1 |
| Mori, S | 1 |
| Ohashi, K | 1 |
| Akiyama, H | 1 |
| Shoji, H | 1 |
| Sato, H | 3 |
| Tanikawa, S | 1 |
| Sakamaki, H | 1 |
| Onozawa, Y | 1 |
| Delmas, V | 1 |
| Billebaud, T | 1 |
| Villers, A | 1 |
| Boccon-Gibod, L | 1 |
| Yamada, T | 1 |
| Dan, K | 1 |
| Nomura, T | 1 |
| Norberg, M | 2 |
| Doershuk, CF | 1 |
| Stern, RC | 1 |
| Fukuoka, Y | 1 |
| Ikeda, Y | 1 |
| Yamashiro, Y | 1 |
| Takahata, M | 1 |
| Todo, Y | 1 |
| Narita, H | 1 |
| Imperiale, TF | 1 |
| Esber, EJ | 1 |
| Aus, G | 2 |
| Hermansson, CG | 1 |
| Hugosson, J | 2 |
| Pedersen, KV | 1 |
| Ahlgren, G | 1 |
| Bergdahl, S | 1 |
| Saint-Blancat, P | 1 |
| Burucoa, C | 1 |
| Boissonnot, M | 1 |
| Gobert, F | 1 |
| Risse, JF | 1 |
| Holmberg, L | 1 |
| Häggman, M | 1 |
| Magnusson, A | 1 |
| Novella, M | 1 |
| Solà, R | 1 |
| Soriano, G | 5 |
| Andreu, M | 1 |
| Gana, J | 1 |
| Ortiz, J | 2 |
| Coll, S | 1 |
| Sàbat, M | 2 |
| Vila, MC | 1 |
| Vilardell, F | 2 |
| Younossi, ZM | 1 |
| McHutchison, JG | 1 |
| Ganiats, TG | 1 |
| Glück, T | 1 |
| Nagatomo, A | 1 |
| Watanabe, K | 1 |
| Kunikane, H | 1 |
| Okamoto, H | 1 |
| Kunitoh, H | 1 |
| Martino, R | 1 |
| Subira, M | 1 |
| Altés, A | 1 |
| López, R | 1 |
| Sureda, A | 1 |
| Domingo-Albós, A | 1 |
| Pericas, R | 1 |
| Brunet, S | 1 |
| Kolle, L | 1 |
| Pamplona, J | 1 |
| Novella, MT | 1 |
| Villanueva, C | 3 |
| Sainz, S | 2 |
| Torras, J | 1 |
| Balanzó, J | 3 |
| Jeffries, MA | 1 |
| Stern, MA | 1 |
| Gunaratnam, NT | 1 |
| Fontana, RJ | 1 |
| Pandeya, SN | 1 |
| Sriram, D | 1 |
| Nath, G | 1 |
| De Clercq, E | 1 |
| Amaro Martins, VC | 1 |
| Goissis, G | 1 |
| Cahen, P | 1 |
| Honderlick, P | 1 |
| Fukuyama, M | 1 |
| Furuhata, K | 1 |
| Oonaka, K | 1 |
| Hara, T | 1 |
| Sunakawa, K | 2 |
| Gómez, J | 1 |
| Colmenero, J | 1 |
| Vila, J | 2 |
| Rodés, J | 3 |
| Campillo, B | 1 |
| Dupeyron, C | 1 |
| Richardet, JP | 1 |
| Bauer, TM | 1 |
| Stahlmann, R | 1 |
| Zwaveling, JH | 1 |
| Maring, JK | 1 |
| Klompmaker, IJ | 1 |
| Haagsma, EB | 1 |
| Bottema, JT | 1 |
| Laseur, M | 1 |
| Winter, HL | 1 |
| van Enckevort, PJ | 1 |
| TenVergert, EM | 1 |
| Metselaar, HJ | 1 |
| Bruining, HA | 1 |
| Slooff, MJ | 1 |
| Hosaka, M | 2 |
| Yasue, T | 1 |
| Fukuda, H | 1 |
| Tomizawa, H | 1 |
| Aoyama, H | 2 |
| Tomás, A | 2 |
| Torras, X | 1 |
| González, D | 1 |
| Anguera, A | 1 |
| Cussó, X | 1 |
| Grangé, JD | 1 |
| Amiot, X | 1 |
| Drinovec, J | 1 |
| D'Antonio, D | 2 |
| Iacone, A | 1 |
| Fioritoni, G | 1 |
| Betti, S | 1 |
| Dell'Isola, M | 1 |
| Quaglietta, AM | 1 |
| Accorsi, P | 1 |
| Pantalone, V | 1 |
| Recchia, A | 1 |
| Piergallini, A | 1 |
| Salmerón, JM | 2 |
| Titó, L | 1 |
| Rimola, A | 2 |
| Mas, A | 1 |
| Navasa, MA | 1 |
| Llach, J | 2 |
| Ginès, A | 1 |
| Ginès, P | 2 |
| Miller, IM | 1 |
| Vogel, R | 1 |
| Cook, TJ | 1 |
| Wittreich, J | 1 |
| Thornton, SA | 1 |
| Wignall, SF | 1 |
| Kilpatrick, ME | 1 |
| Bourgeois, AL | 1 |
| Gardiner, C | 1 |
| Batchelor, RA | 1 |
| Burr, DH | 1 |
| Oprandy, JJ | 1 |
| Garst, P | 1 |
| Hyams, KC | 1 |
| Sampi, K | 1 |
| Maseki, N | 1 |
| Hattori, M | 1 |
| Huber-Spitzy, V | 1 |
| Baumgartner, I | 1 |
| Arocker-Mettinger, E | 1 |
| Schiffbänker, M | 1 |
| Georgiew, L | 1 |
| Grabner, G | 1 |
| Waites, KB | 1 |
| Canupp, KC | 1 |
| DeVivo, MJ | 1 |
| Brody, T | 1 |
| Pensak, ML | 1 |
| Schubert, ML | 1 |
| Sanyal, AJ | 1 |
| Wong, ES | 1 |
| Teixidó, M | 2 |
| Barrios, J | 1 |
| Enríquez, J | 1 |
| Gargallo-Viola, D | 1 |
| Esteve, M | 2 |
| Llovera, S | 1 |
| Roca, X | 1 |
| Guinea, J | 1 |
| Méndez, C | 1 |
| Tena, F | 1 |
| Fábrega, E | 1 |
| Fujii, R | 2 |
| Meguro, H | 2 |
| Arimasu, O | 1 |
| Ushijima, K | 2 |
| Abe, T | 2 |
| Nakazawa, S | 3 |
| Narita, A | 2 |
| Niino, K | 2 |
| Ichihashi, H | 1 |
| Vargas, V | 1 |
| Marco, F | 1 |
| Almela, M | 1 |
| Forné, M | 1 |
| Miranda, ML | 1 |
| Hoefs, JC | 1 |
| Iwai, N | 1 |
| Nakamura, H | 1 |
| Miyazu, M | 1 |
| Katayama, M | 1 |
| Kasai, K | 1 |
| Morikawa, M | 1 |
| Tokunaka, S | 1 |
| Yachiku, S | 1 |
| Yamauchi, K | 1 |
| Wakabayashi, A | 1 |
| Inagaki, N | 1 |
| Nishihara, M | 1 |
| Yamaguchi, S | 1 |
| Nonaka, C | 1 |
| Shinozaki, T | 1 |
| Matsumoto, K | 1 |
| Suzuki, H | 1 |
| Nakanishi, Y | 1 |
| Toyonaga, Y | 1 |
| Koizumi, M | 1 |
| Imai, H | 1 |
| Sakaguchi, N | 1 |
| Sugita, M | 1 |
| Fukushima, Y | 1 |
| Yamasaki, M | 1 |
| Sato, Y | 1 |
| Iwata, S | 1 |
| Akita, H | 1 |
| Nishimura, T | 1 |
| Tabuki, K | 1 |
| Aoki, S | 1 |
| Takagi, M | 1 |
| Haruta, T | 1 |
| Kuroki, S | 1 |
| Okura, K | 1 |
| Kobayashi, Y | 1 |
| Okada, T | 1 |
| Furukawa, S | 1 |
| Renneberg, J | 1 |
| Walder, M | 1 |
| Del Favero, A | 2 |
| Bucaneve, G | 2 |
| Minetti, B | 1 |
| Ricci, P | 1 |
| Landonio, G | 1 |
| Montillo, M | 1 |
| Malleo, C | 1 |
| Qadri, SM | 1 |
| Lee, G | 1 |
| Brodie, L | 1 |
| Kotera, Y | 1 |
| Mladenov, D | 1 |
| Tsvetkov, M | 1 |
| Kumanov, Kh | 1 |
| Naumann, P | 1 |
| Dopp, C | 1 |
| Nord, CE | 3 |
| Edlund, C | 3 |
| Cuervas-Mons, V | 1 |
| Barrios, C | 1 |
| Garrido, A | 1 |
| Escartin, P | 1 |
| Arcas, M | 1 |
| Portero, F | 1 |
| Mora, NP | 1 |
| Turrion, VS | 1 |
| Herrera, J | 1 |
| Pereira, F | 1 |
| Arakawa, S | 1 |
| Takagi, S | 1 |
| Maeda, H | 1 |
| Ka, S | 1 |
| Matsumoto, O | 1 |
| Kamidono, S | 1 |
| Umezu, K | 1 |
| Kawabata, G | 1 |
| Fujii, A | 1 |
| Morishita, S | 1 |
| Hooper, DC | 1 |
| Wolfson, JS | 1 |
| Chan, MK | 2 |
| Wong, WT | 2 |
| Cheng, IK | 2 |
| Ulrich, C | 1 |
| Harinck-de Weerd, JE | 1 |
| Bakker, NC | 1 |
| Jacz, K | 1 |
| Doornbos, L | 1 |
| de Ridder, VA | 1 |
| Murray, BE | 1 |
| Nemet, D | 1 |
| Kalenic, S | 1 |
| Badanjak, A | 1 |
| Bogdanic, V | 1 |
| Davila, N | 1 |
| Francetić, I | 1 |
| Labar, B | 1 |
| Desgrandchamps, D | 1 |
| Munzinger, J | 1 |
| Menichetti, F | 1 |
| Felicini, R | 1 |
| Aversa, F | 1 |
| Greco, M | 1 |
| Pasquarella, C | 1 |
| Moretti, MV | 1 |
| Martelli, MF | 1 |
| Kurobe, N | 1 |
| Sakaguchi, Y | 1 |
| Yoshida, H | 1 |
| Kojima, T | 1 |
| Ohue, T | 1 |
| Klietmann, W | 1 |
| Focht, J | 1 |
| Nösner, K | 1 |
| Lahnborg, G | 1 |
| Manzo, M | 1 |
| Guimaraes, MA | 1 |
| Noone, P | 1 |
| Davies, BI | 2 |
| Maesen, FP | 2 |
| Teengs, JP | 2 |
| Baur, C | 2 |
| Kelley, SG | 1 |
| Bertram, MA | 1 |
| Young, LS | 1 |
| Oomori, Y | 1 |
| Niwata, Y | 1 |
| Fourrier, F | 1 |
| Chopin, C | 1 |
| Lestavel, P | 1 |
| Savage, C | 1 |
| Modak, SM | 1 |
| Sampath, L | 1 |
| Fox, CL | 1 |
| Benvenisty, A | 1 |
| Nowygrod, R | 1 |
| Reemstmau, K | 1 |
| Bayeli, PF | 1 |
| Corsini, P | 1 |
| Marchettini, G | 1 |
| Abate, L | 1 |
| Croci, F | 1 |
| Karb, VB | 1 |
| Winston, DJ | 2 |
| Ho, WG | 2 |
| Nakao, SL | 1 |
| Gale, RP | 1 |
| Champlin, RE | 2 |
| Høiby, N | 1 |
| Karp, J | 1 |
| Bartlett, J | 1 |
| Finley, RS | 1 |
| Joshi, JH | 1 |
| Talbot, G | 1 |
| Levitt, L | 1 |
| Deresinski, S | 1 |
| Ewer, TC | 1 |
| Gilchrist, NL | 1 |
| Aitken, JM | 1 |
| Sainsbury, R | 1 |
| Ueda, Y | 1 |
| Matsumoto, F | 1 |
| Schmeiser, T | 1 |
| Kurrle, E | 1 |
| Arnold, R | 1 |
| Wiesneth, M | 1 |
| Bunjes, D | 1 |
| Hertenstein, B | 1 |
| Kern, W | 1 |
| Heit, W | 1 |
| Heimpel, H | 1 |
| Casali, A | 1 |
| Verri, C | 1 |
| Paoletti, G | 1 |
| Tropea, F | 1 |
| Modugno, G | 1 |
| Frasca, AM | 1 |
| Ameglio, F | 1 |
| Tonachella, R | 1 |
| Gallo Curcio, C | 1 |
| Li, MK | 1 |
| Wong, WS | 1 |
| Yin, PD | 1 |
| Tungsanga, K | 1 |
| Chongthaleong, A | 1 |
| Udomsantisuk, N | 1 |
| Petcharabutr, OA | 1 |
| Sitprija, V | 1 |
| Wong, EC | 1 |
| Lolekha, S | 1 |
| Patanachareon, S | 1 |
| Thanangkul, B | 1 |
| Vibulbandhitkit, S | 1 |
| Pechère, JC | 1 |
| Marchou, B | 1 |
| Michéa-Hamzehpour, M | 1 |
| Auckenthaler, R | 1 |
| Karp, JE | 3 |
| Dick, JD | 1 |
| Merz, WG | 3 |
| Bischoff, W | 1 |
| Modde, H | 1 |
| Edwards, R | 1 |
| Kanematsu, M | 1 |
| Greenwood, D | 1 |
| Dubini, F | 1 |
| Riviera, L | 1 |
| Corrado, ML | 2 |
| Struble, WE | 1 |
| Hesney, M | 1 |
| Haralambie, E | 1 |
| Schmidt-Weinmar, A | 1 |
| Bow, EJ | 1 |
| Rayner, E | 1 |
| Louie, TJ | 1 |
| Lee, C | 1 |
| Ronald, AR | 1 |
| Walker, RC | 1 |
| Wright, AJ | 1 |
| Rowen, RC | 1 |
| Michel, DJ | 1 |
| Thompson, JC | 1 |
| Boland, DM | 1 |
| van Gestel, WC | 1 |
| MacLaren, DM | 1 |
| de Jong, D | 1 |
| Shah, PM | 1 |
| Kuwabara, M | 1 |
| Muroki, K | 1 |
| Fujiue, Y | 1 |
| Ikeda, M | 1 |
| Kodomari, Y | 1 |
| Jyo, T | 1 |
| Yamakido, M | 1 |
| Lauwers, S | 1 |
| Vincken, W | 1 |
| Naessens, A | 1 |
| Pierard, D | 1 |
| Modaï, J | 1 |
| Periti, P | 1 |
| Mazzei, T | 1 |
| Nicoletti, P | 1 |
| Wolff, M | 1 |
| Hirose, T | 1 |
| Okezaki, E | 1 |
| Kato, H | 1 |
| Ito, Y | 1 |
| Bower, RR | 1 |
| Jarvis, KP | 1 |
| Ramer, NR | 1 |
| Shipkowitz, N | 1 |
| Ruiz-Palacios, GM | 1 |
| Hendricksen, C | 2 |
| Laughon, B | 2 |
| Redden, T | 2 |
| Bamberger, BJ | 2 |
| Bartlett, JG | 2 |
| Saral, R | 2 |
| Burke, PJ | 2 |
| Wang, C | 1 |
| Sabbaj, J | 1 |
| Corrado, M | 1 |
| Hoagland, V | 1 |
| Cynamon, MH | 1 |
| Wilcox, GH | 1 |
| Eggleston, M | 1 |
| Heseltine, PN | 1 |
| Goldstein, EJ | 1 |
| Citron, DM | 1 |
| Bendon, L | 1 |
| Vagvolgyi, AE | 1 |
| Trousdale, MD | 1 |
| Appleman, MD | 1 |
| Xicota, MA | 1 |
| Coll, R | 1 |
| Moros, M | 1 |
| Parés, J | 1 |
| Karachalios, GN | 1 |
| Georgiopoulos, AN | 1 |
| Castelli, M | 1 |
| Barbieri, ML | 1 |
| Bertolini, A | 1 |
| Bossa, R | 1 |
| Galatulas, I | 1 |
| Mascellino, MT | 1 |
| Lorenzi, A | 1 |
| Bonanni, M | 1 |
| Iegri, F | 1 |
| Kumada, T | 1 |
| Bertrand, A | 1 |
| Janbon, F | 1 |
| Jourdan, J | 1 |
| Jonquet, O | 1 |
| Santoni, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rifaximin Versus Norfloxacin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis[NCT04159870] | Phase 3 | 322 participants (Anticipated) | Interventional | 2019-11-05 | Active, not recruiting | ||
| The Efficacy and Safety of Rifaximin In The Treatment of HBV Associated Acute-on-Chronic Liver Failure Patients With Mild to Moderate Hepatic Encephalopathy[NCT05786859] | Early Phase 1 | 124 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding[NCT00838864] | Phase 4 | 79 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Patterns of Antibiotic Resistant Bacterial Infections in Liver Intensive Care Unit[NCT03855709] | 200 participants (Anticipated) | Observational | 2019-05-31 | Not yet recruiting | |||
| Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients[NCT01542801] | Phase 4 | 124 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients[NCT05621005] | Phase 2 | 104 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for norfloxacin and Bacterial Disease
| Article | Year |
|---|---|
Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Dose-Response Relationship, Drug; Humans; Mic | 2019 |
Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
Topics: Anti-Bacterial Agents; Bacterial Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; | 2019 |
Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis.
Topics: Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Multiple, Bacterial; Humans; Incidenc | 2020 |
Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis.
Topics: Antibiotic Prophylaxis; Bacterial Infections; Drug Therapy, Combination; Female; Humans; Norfloxacin | 2019 |
Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Humans; Incidence; Norfloxacin; | 2019 |
Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Humans; Network Meta-Analysis; Norfloxac | 2019 |
Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Ciprofloxacin; Endoscopy; Esoph | 2014 |
Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; Bacterial Tr | 2015 |
Short term therapy for uncomplicated urinary tract infection today. Clinical outcome upholds the theories.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalexin; Clinical Trials as Topic; Dose-Response Rel | 2003 |
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
[Spontaneous bacterial peritonitis in liver cirrhosis with ascites].
Topics: Anti-Bacterial Agents; Ascites; Bacteria; Bacterial Infections; Blood; Endoscopy; Humans; Leukocyte | 1995 |
[Spontaneous bacterial peritonitis].
Topics: Animals; Ascites; Bacterial Infections; Bacterial Translocation; Cefotaxime; Diagnosis, Differential | 1998 |
[Prophylaxis of infectious complications by selective digestive bacterial decontamination in patients with cirrhosis].
Topics: Anti-Bacterial Agents; Ascitic Fluid; Bacterial Infections; Decontamination; Digestive System Diseas | 1992 |
Clinical impact of newer quinolones: influence on normal microflora.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Immune Tolerance; Intestinal Mucosa; Norfloxacin; Oroph | 1989 |
Norfloxacin, ciprofloxacin, and ofloxacin: current clinical roles.
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Drug Tolerance; Humans; Norfloxacin; Ofloxacin | 1989 |
Quinolones and the gastrointestinal tract.
Topics: Agranulocytosis; Anti-Infective Agents; Bacterial Infections; Biliary Tract Diseases; Diarrhea; Drug | 1989 |
Two new fluoroquinolones: ciprofloxacin and norfloxacin.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Norfloxacin | 1988 |
[Current antimicrobial agent series III: Norfloxacin].
Topics: Animals; Bacteria; Bacterial Infections; Drug Evaluation; Drug Resistance, Microbial; Humans; Mice; | 1988 |
Manipulation of the oropharyngeal and intestinal microflora by norfloxacin: microbiological and clinical aspects.
Topics: Bacteria; Bacterial Infections; Humans; Immune Tolerance; Intestines; Norfloxacin; Oropharynx; Urina | 1988 |
Norfloxacin: its potential in clinical practice.
Topics: Bacterial Infections; Diarrhea; Gonorrhea; Humans; Neutropenia; Norfloxacin; Travel; Urinary Tract I | 1987 |
Symposium on antimicrobial agents. The quinolones.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1987 |
Norfloxacin: clinical pharmacology and clinical use.
Topics: Bacteria; Bacterial Infections; Drug Resistance, Microbial; Humans; Norfloxacin | 1987 |
Quinolones.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Enoxacin | 1987 |
Norfloxacin in the treatment of bacterial enteric infections.
Topics: Bacterial Infections; Diarrhea; Enteritis; Humans; Norfloxacin | 1986 |
Principles for targeted antibiotic use in urinary tract and enteric infections: a review with special emphasis on norfloxacin.
Topics: Bacterial Infections; Drug Resistance, Microbial; Enteritis; Humans; Norfloxacin; Urinary Tract Infe | 1986 |
World-wide clinical experience with norfloxacin: efficacy and safety.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Gastroente | 1986 |
New antibiotics: areas of appropriate use.
Topics: Anti-Bacterial Agents; Aztreonam; Bacterial Infections; beta-Lactamase Inhibitors; Cephalosporins; C | 1987 |
The role of 4-quinolones in the treatment of infections.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Kinetics; Norfloxacin; Ofloxacin; Oxazines; Urinary Tra | 1987 |
Review of the 4-quinolones.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Interactions; Drug Resist | 1987 |
50 trials available for norfloxacin and Bacterial Disease
| Article | Year |
|---|---|
Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial.
Topics: Acute-On-Chronic Liver Failure; Bacterial Infections; Double-Blind Method; Humans; Liver Cirrhosis; | 2022 |
Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; Ciprofloxacin; Disease-Free Survi | 2018 |
A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial I | 2014 |
The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.
Topics: Adult; Anti-Bacterial Agents; Ascites; Bacterial Infections; Female; Humans; Interleukin-10; Interle | 2015 |
Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.
Topics: Adult; Aged; Antibiotic Prophylaxis; Bacterial Infections; Drug Administration Schedule; Female; Hum | 2016 |
Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ascites; Bacterial Infections; Cause of Death; Egypt; | 2016 |
Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Cohort Studies; Cross-Over Studies; Cytokines; Fe | 2009 |
Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial.
Topics: Adolescent; Adult; Aged; Antibiotic Prophylaxis; Bacterial Infections; Combined Modality Therapy; Do | 2012 |
[Factors participating in development of bleeding varices in portal hypertension. Part I: bacterial infection and comparison of intravenous and peroral antibiotics effects--a randomised study].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Bacterial I | 2004 |
Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics--a randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Bacterial I | 2005 |
Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Ba | 2006 |
Use of norfloxacin for prevention of symptomatic urinary tract infection in chronically catheterized patients.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Cross- | 1995 |
Tosulfloxacin versus norfloxacin for prevention of infections in chemotherapy-induced neutropenic patients.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antineoplastic Agents; Bacterial Infections; Drug Ev | 1994 |
Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B.
Topics: Administration, Oral; Adult; Amphotericin B; Antineoplastic Agents; Bacterial Infections; Drug Combi | 1993 |
Infection after transrectal core biopsies of the prostate--risk factors and antibiotic prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Biopsy, Needle; Humans; | 1996 |
Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.
Topics: Anti-Infective Agents; Ascites; Bacterial Infections; Drug Administration Schedule; Drug Resistance, | 1997 |
A randomized controlled trial of sulfamethoxazole/trimethoprim plus norfloxacin versus sulfamethoxazole/trimethoprim alone for the prophylaxis of bacteria infection during chemotherapy for lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Combin | 1998 |
Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Bacterial Infections; Ceftriaxone; Cephalosporins | 1998 |
Selective decontamination of the digestive tract to prevent postoperative infection: a randomized placebo-controlled trial in liver transplant patients.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Decontaminati | 2002 |
Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Adult; Aged; Bacterial Infections; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Mal | 1992 |
Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Adult; Aged; Bacterial Infections; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Mal | 1992 |
Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Adult; Aged; Bacterial Infections; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Mal | 1992 |
Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Adult; Aged; Bacterial Infections; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Mal | 1992 |
Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacteremia; Bacterial Infections; Female; Fever; Hum | 1992 |
Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure.
Topics: Adult; Bacterial Infections; Colistin; Enterobacteriaceae; Female; Gram-Negative Bacteria; Gram-Posi | 1992 |
Topically administered norfloxacin compared with topically administered gentamicin for the treatment of external ocular bacterial infections. The Worldwide Norfloxacin Ophthalmic Study Group.
Topics: Administration, Topical; Adolescent; Adult; Aged; Bacterial Infections; Blepharitis; Conjunctivitis; | 1992 |
Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa.
Topics: Acute Disease; Adolescent; Adult; Africa, Western; Bacterial Infections; Diarrhea; Escherichia coli | 1992 |
[A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study].
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Bacterial Infections; Bone Marrow Transplant | 1992 |
Efficacy and tolerance of norfloxacin in treatment of complicated urinary tract infection in outpatients with neurogenic bladder secondary to spinal cord injury.
Topics: Adult; Bacterial Infections; Drug Administration Schedule; Drug Tolerance; Female; Humans; Male; Mic | 1991 |
Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis?
Topics: Bacterial Infections; Cost-Benefit Analysis; Humans; Liver Cirrhosis; Norfloxacin; Peritonitis | 1991 |
Selective intestinal decontamination prevents spontaneous bacterial peritonitis.
Topics: Aged; Ascitic Fluid; Bacterial Infections; Female; Hospitalization; Humans; Intestines; Liver Cirrho | 1991 |
Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fever; | 1991 |
[Evaluation of norfloxacin in the pediatric field. Pediatric Study Group for Norfloxacin].
Topics: Administration, Oral; Bacterial Infections; Campylobacter Infections; Child; Child, Preschool; Drug | 1990 |
Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial.
Topics: Bacterial Infections; Double-Blind Method; Drug Administration Schedule; Feces; Female; Humans; Live | 1990 |
[Prophylaxis using quinolones in neutropenic patients. Preliminary results of a cooperative study by the Grupo Italiano Malattie Ematologiche maligne dell'adulto (GIMEMEA)].
Topics: Agranulocytosis; Anti-Bacterial Agents; Bacterial Infections; Bone Marrow Transplantation; Ciproflox | 1989 |
[Clinical study of norfloxacin in the treatment of acute epididymitis].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacterial Infections; Clinical Trials as Topic; Epidi | 1989 |
A double-blind controlled trial of norfloxacin versus cotrimoxazole in the treatment of urinary tract infections.
Topics: Adult; Anti-Infective Agents, Urinary; Bacterial Infections; Double-Blind Method; Female; Humans; Ma | 1989 |
Selective decontamination of the digestive tract with norfloxacin in the prevention of ICU-acquired infections: a prospective randomized study.
Topics: Bacterial Infections; Cross Infection; Digestive System; Female; Gram-Negative Bacteria; Humans; Inc | 1989 |
Prevention of gram-negative bacterial infection in granulocytopenic patients: a randomized study comparing oral norfloxacin with gentamycin.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Bacterial Infections; Gentamicins; Gram-Ne | 1989 |
[Initial antibiotherapy in severe bacterial bronchopneumopathies. Randomized study of a new quinolone: pefloxacin].
Topics: Anti-Infective Agents; Bacterial Infections; Bronchopneumonia; Humans; Norfloxacin; Pefloxacin | 1986 |
Norfloxacin for prevention of bacterial infections in granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Drug Combinations; Drug Therapy, Com | 1987 |
Comparative study of norfloxacin and trimethoprim for the treatment of elderly patients with urinary tract infection.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Bacteriuria; Clinical Trials as Topic; Enterobacteria | 1988 |
Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin.
Topics: Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Drug Evaluation; Humans; Neoplasms; | 1988 |
Treatment of urinary tract infections in Hong Kong: a comparative study of norfloxacin and co-trimoxazole.
Topics: Adult; Bacterial Infections; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug | 1988 |
Norfloxacin versus co-trimoxazole for the treatment of upper urinary tract infections: a double blind trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Clinical Trials as Topic; Double-B | 1988 |
Norfloxacin versus co-trimoxazole in the treatment of acute bacterial diarrhoea: a placebo controlled study.
Topics: Acute Disease; Adult; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Double-Blind Method; | 1988 |
The tolerability profile of prophylactic norfloxacin in neutropenic patients.
Topics: Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Colistin; Diarrhea; Gastrointestina | 1988 |
Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis.
Topics: Acute Disease; Adult; Antineoplastic Agents; Bacterial Infections; Clinical Trials as Topic; Drug Co | 1988 |
Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit.
Topics: Bacterial Infections; Clinical Trials as Topic; Critical Care; Drug Resistance, Microbial; Humans; N | 1987 |
Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Agranulocytosis; Bacterial Infections; Clinical Tr | 1986 |
World-wide clinical experience with norfloxacin: efficacy and safety.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Gastroente | 1986 |
Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents | 1987 |
Norfloxacin versus nalidixic acid in the treatment of urinary tract infections.
Topics: Adult; Aged; Bacterial Infections; Bacteriuria; Female; Humans; Male; Middle Aged; Nalidixic Acid; N | 1987 |
136 other studies available for norfloxacin and Bacterial Disease
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
Topics: Actinobacillus Infections; Actinobacillus pleuropneumoniae; Aerobiosis; Anaerobiosis; Animals; Anti- | 1992 |
New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk.
Topics: 4-Quinolones; Administration, Oral; Animals; Anti-Infective Agents; Bacterial Infections; Female; In | 1992 |
Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship.
Topics: Alkylation; Aminoquinolines; Animals; Anti-Bacterial Agents; Bacterial Infections; Chemical Phenomen | 1991 |
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Female; Fluorine; Magnetic Resonance Spectrosc | 1987 |
Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents.
Topics: Acinetobacter; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Chemical | 1985 |
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacteria; Bacterial Infections; Bacterial Proteins | 2008 |
Synthesis and antimicrobial activity of novel fluorine containing 4-(substituted-2-hydroxybenzoyl)-1H-pyrazoles and pyrazolyl benzo[d]oxazoles.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bacillus subtilis; Bacteria; Bacter | 2010 |
Synthesis of new chalcone derivatives bearing 2,4-thiazolidinedione and benzoic acid moieties as potential anti-bacterial agents.
Topics: Anti-Bacterial Agents; Bacterial Infections; Benzoic Acid; Cell Proliferation; Chalcone; Drug Resist | 2011 |
Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; Green Chemistry | 2012 |
Synthesis and study of 1-ethyl-3-carbohydrazide and 3-[1-oxo-2-hydrazino-3-{p-toluenesulfon}]quinolone derivatives against bacterial infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Escherichia coli; Hyd | 2013 |
Synthesis and antimicrobial activity of polyhalobenzonitrile quinazolin-4(3H)-one derivatives.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bacteria; Bacterial Infections; Can | 2013 |
Synthesis and biological evaluation of α-triazolyl chalcones as a new type of potential antimicrobial agents and their interaction with calf thymus DNA and human serum albumin.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Cattle; Chalcones; DNA; Fungi; Human | 2014 |
Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
Topics: Anti-Infective Agents; Antimalarials; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; | 2016 |
Novel benzimidazolyl tetrahydroprotoberberines: Design, synthesis, antimicrobial evaluation and multi-targeting exploration.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Benzimidazoles; Berberine Alkaloids; | 2017 |
Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.
Topics: Bacterial Infections; Biofilms; Drug Resistance, Multiple; Electron Transport Chain Complex Proteins | 2019 |
Synthesis and Bioevaluation of Novel Technetium-99m-Labeled Complexes with Norfloxacin HYNIC Derivatives for Bacterial Infection Imaging.
Topics: Animals; Bacterial Infections; Mice; Norfloxacin; Organotechnetium Compounds; Radiopharmaceuticals; | 2023 |
Synthesis and Bioevaluation of Novel Technetium-99m-Labeled Complexes with Norfloxacin HYNIC Derivatives for Bacterial Infection Imaging.
Topics: Animals; Bacterial Infections; Mice; Norfloxacin; Organotechnetium Compounds; Radiopharmaceuticals; | 2023 |
Synthesis and Bioevaluation of Novel Technetium-99m-Labeled Complexes with Norfloxacin HYNIC Derivatives for Bacterial Infection Imaging.
Topics: Animals; Bacterial Infections; Mice; Norfloxacin; Organotechnetium Compounds; Radiopharmaceuticals; | 2023 |
Synthesis and Bioevaluation of Novel Technetium-99m-Labeled Complexes with Norfloxacin HYNIC Derivatives for Bacterial Infection Imaging.
Topics: Animals; Bacterial Infections; Mice; Norfloxacin; Organotechnetium Compounds; Radiopharmaceuticals; | 2023 |
Synthesis and Bioevaluation of Novel Technetium-99m-Labeled Complexes with Norfloxacin HYNIC Derivatives for Bacterial Infection Imaging.
Topics: Animals; Bacterial Infections; Mice; Norfloxacin; Organotechnetium Compounds; Radiopharmaceuticals; | 2023 |
Synthesis and Bioevaluation of Novel Technetium-99m-Labeled Complexes with Norfloxacin HYNIC Derivatives for Bacterial Infection Imaging.
Topics: Animals; Bacterial Infections; Mice; Norfloxacin; Organotechnetium Compounds; Radiopharmaceuticals; | 2023 |
Synthesis and Bioevaluation of Novel Technetium-99m-Labeled Complexes with Norfloxacin HYNIC Derivatives for Bacterial Infection Imaging.
Topics: Animals; Bacterial Infections; Mice; Norfloxacin; Organotechnetium Compounds; Radiopharmaceuticals; | 2023 |
Synthesis and Bioevaluation of Novel Technetium-99m-Labeled Complexes with Norfloxacin HYNIC Derivatives for Bacterial Infection Imaging.
Topics: Animals; Bacterial Infections; Mice; Norfloxacin; Organotechnetium Compounds; Radiopharmaceuticals; | 2023 |
Synthesis and Bioevaluation of Novel Technetium-99m-Labeled Complexes with Norfloxacin HYNIC Derivatives for Bacterial Infection Imaging.
Topics: Animals; Bacterial Infections; Mice; Norfloxacin; Organotechnetium Compounds; Radiopharmaceuticals; | 2023 |
Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Cross-Sectional Studies; Drug R | 2023 |
Impact of Prophylactic Norfloxacin in Multidrug Resistant Bacterial Infections in the Early Liver Posttransplant Period.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; End Stage Liver Disease; Humans; Liver Cirrhosis | 2023 |
Hybrid nanoparticles for the topical delivery of norfloxacin for the effective treatment of bacterial infection produced after burn.
Topics: Animals; Bacterial Infections; Burns; Calorimetry, Differential Scanning; Drug Carriers; Microbial S | 2017 |
Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Bacterial Translocation; Carbon Tetrachloride; | 2018 |
Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Female; Humans; Li | 2019 |
Bacterial profile and antimicrobial susceptibility patterns in chronic suppurative otitis media at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Chronic Disease; Ciprofloxacin; Clarithromyci | 2019 |
Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis.
Topics: Aged; Bacterial Infections; Bacterial Translocation; Depression, Chemical; Drug Interactions; Female | 2015 |
Selective intestinal decontamination with norfloxacin enhances a regulatory T cell-mediated inflammatory control mechanism in cirrhosis.
Topics: Adoptive Transfer; Aged; Animals; Anti-Bacterial Agents; B7-1 Antigen; B7-2 Antigen; Bacterial Infec | 2016 |
Synthesis and biodistribution of a novel (⁹⁹m)TcN complex of norfloxacin dithiocarbamate as a potential agent for bacterial infection imaging.
Topics: Animals; Bacterial Infections; Drug Stability; Electrophoresis, Paper; Inflammation; Isotope Labelin | 2011 |
Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fluoroquinolones; H | 2011 |
Preparation and stability study of norfloxacin-loaded solid lipid nanoparticle suspensions.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Drug Stability; Male; Mice; Microbial Sensitiv | 2012 |
Probiotics: should we be more definitive in terminology?
Topics: Bacterial Infections; Female; Humans; Male; Norfloxacin; Peritonitis; Probiotics | 2012 |
Urinary tract infections in South Croatia: aetiology and antimicrobial resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Bacterial Infections; Ceftibuten; Cephalosporins; Clavulanic Aci | 2003 |
Synthesis, degradation, and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Dextrans; Dru | 2003 |
Norfloxacin-loaded chitosan sponges as wound dressing material.
Topics: Administration, Topical; Adsorption; Anti-Infective Agents; Bacterial Infections; Bandages; Biocompa | 2004 |
Increased orocecal transit time in patients with nonalcoholic fatty liver disease.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Breath Tests; Fatty Liver; Female; Gastrointesti | 2005 |
Effects of norfloxacin or pefloxacin on the oral and intestinal microflora of bone marrow transplant patients.
Topics: Adolescent; Adult; Anti-Infective Agents; Bacterial Infections; Bone Marrow Transplantation; Female; | 1989 |
The use of quinolones in the treatment of acute bacterial diarrhea: a comparative therapeutic trial.
Topics: Acute Disease; Adolescent; Anti-Infective Agents; Bacteria; Bacterial Infections; Chloramphenicol; D | 1989 |
Clinical trial of norfloxacin in the treatment of bacterial enteritis.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Enteritis; Femal | 1989 |
Efficacy of long-term therapy with norfloxacin in chronic bacterial prostatitis.
Topics: Acute Disease; Adult; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Humans; Male; Mi | 1989 |
Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.
Topics: Anti-Infective Agents; Ascites; Bacterial Infections; Cisapride; Drug Therapy, Combination; Gastroin | 2006 |
Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Infections; | 2007 |
Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Female; Humans; Male; Mid | 2008 |
Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; DNA, Bacterial; Female; Humans; I | 2008 |
Norfloxacin and the antibacterial gamma pyridone beta carboxylic acids.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Humans; Microbial Sensitivity Tests; Nalidixi | 1982 |
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactams; Microbial Sens | 1982 |
In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Digestive System; Drug Combinations; Drug Res | 1983 |
Norfloxacin penetration into subcutaneous tissue cage fluid in rabbits and efficacy in vivo.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Escherichia coli Infections; Klebsiella Infect | 1983 |
Norfloxacin for the treatment of uncomplicated urinary tract infections.
Topics: Adult; Bacterial Infections; Drug Evaluation; Female; Humans; Nalidixic Acid; Norfloxacin; Urinary T | 1983 |
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Stability; Enoxacin; Humans; Microbial S | 1983 |
Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Enoxacin; Gentamicins; Male; Mice; Nalidixic A | 1983 |
In vitro and in vivo antibacterial activity of AT-2266.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enoxacin | 1983 |
Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enterobacteriacea | 1984 |
The in vitro and in vivo activity of ciprofloxacin.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; | 1984 |
In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
Topics: Bacteria; Bacterial Infections; Enoxacin; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Napht | 1984 |
Antibacterial efficacy of norfloxacin, trimethoprim-sulfamethoxazole, and gentamicin in experimentally-infected normal and streptozotocin-induced diabetic mice.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Diabetes Mellitus, Experimental; Dru | 1984 |
In vitro antibacterial activity of AM-715, a new nalidixic acid analog.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Culture Media; Drug Resistance, Microbial; Hu | 1980 |
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Mice; Nalidixic Acid; Nicotinic Acids; Norflox | 1981 |
Antibiotic pharmacokinetics in the inflamed prostate.
Topics: Animals; Bacterial Infections; Chronic Disease; Male; Norfloxacin; Prostatitis; Rats; Rats, Sprague- | 1995 |
Preventing biliary stent occlusion.
Topics: Bacterial Infections; Cholestasis; Drug Therapy, Combination; Humans; Norfloxacin; Stents; Ursodeoxy | 1994 |
[Complications of prostatic biopsy. An analysis of a series of 4764 biopsies].
Topics: Anti-Bacterial Agents; Bacterial Infections; Biopsy; France; Humans; Male; Norfloxacin; Pefloxacin; | 1993 |
Transrectal ultrasound and core biopsies for the diagnosis of prostate cancer. A study of pretreatment investigation strategy for patients with suspected prostate cancer.
Topics: Aged; Bacterial Infections; Biopsy, Needle; Diagnostic Techniques, Surgical; Equipment Design; Follo | 1994 |
Spontaneous bacterial peritonitis in cystic fibrosis.
Topics: Adolescent; Adult; Bacterial Infections; Cystic Fibrosis; Female; Humans; Liver Cirrhosis; Male; Nor | 1994 |
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Lung Diseases | 1993 |
Preventing infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Bacteremia; Bacterial Infections; Biometry; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; No | 1993 |
Transrectal ultrasound examination of the prostate: complications and acceptance by patients.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Biopsy, Needle; Humans; Male; Middle Aged; Nor | 1993 |
[Search for bacterial contamination of the aqueous humor during cataract surgery with and without local antibiotic prophylaxis].
Topics: Administration, Topical; Anti-Infective Agents; Antibiotic Prophylaxis; Aqueous Humor; Bacterial Inf | 1995 |
Determinants of complications after multiple transrectal core biopsies of the prostate.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Biopsy, Needle; Blood; | 1996 |
An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis.
Topics: Anti-Infective Agents; Bacterial Infections; Cost Savings; Health Care Costs; Humans; Life Expectanc | 1997 |
Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial Infect | 1998 |
Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis.
Topics: Adult; Aged; Ambulatory Care; Anti-Infective Agents; Antibiotic Prophylaxis; Ascites; Ascitic Fluid; | 1999 |
Synthesis, antibacterial, antifungal and anti-HIV activities of norfloxacin mannich bases.
Topics: Animals; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Bacteria; Bacterial Infections; | 2000 |
Nonstoichiometric hydroxyapatite-anionic collagen composite as support for the double sustained release of gentamicin and norfloxacin/ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Biocompatible Materials | 2000 |
[Nitrofurans: a modern treatment for uncomplicated urinary infections?].
Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Drug Resistance, Microbial; Enterobacteriaceae | 2000 |
[Antibacterial activity of fosfomycin against the causative bacteria isolated from bacterial enteritis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Blood; Campylobacter; Electrolyt | 2000 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis.
Topics: Anti-Infective Agents; Bacterial Infections; Carrier State; Cross Infection; Female; France; Humans; | 2001 |
Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis.
Topics: Animals; Anti-Bacterial Agents; Ascitic Fluid; Bacteria; Bacterial Infections; Bacterial Translocati | 2002 |
Clinical toxicological aspects of fluoroquinolones.
Topics: Anti-Infective Agents; Bacterial Infections; Cardiovascular Diseases; Central Nervous System Disease | 2002 |
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; DNA Topoisomerases, Type II; Dr | 1992 |
[The clinical use of norfloxacin (Nolicin) and ciprofloxacin (Ciprinol)].
Topics: Bacterial Infections; Ciprofloxacin; Humans; Norfloxacin | 1992 |
[Corneal ulcer. Current analysis from specialized ambulatory care of a clinic].
Topics: Ambulatory Care; Anti-Bacterial Agents; Bacterial Infections; Contact Lenses, Extended-Wear; Corneal | 1992 |
The fluoroquinolones.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Norfloxacin; Otitis Externa | 1991 |
In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Evaluation, Prec | 1991 |
[An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination].
Topics: Ascites; Bacterial Infections; Cross Infection; Decontamination; Female; Humans; Incidence; Intestin | 1991 |
Spontaneous bacterial peritonitis: prevention and therapy.
Topics: Anti-Bacterial Agents; Bacterial Infections; Humans; Liver Cirrhosis; Norfloxacin; Peritonitis | 1990 |
[Basic and clinical studies on norfloxacin in the pediatric field].
Topics: Adolescent; Bacteria; Bacterial Infections; Child; Child, Preschool; Drug Evaluation; Female; Half-L | 1990 |
[The therapeutic effect of norfloxacin on chronic prostatitis].
Topics: Adult; Aged; Bacterial Infections; Chronic Disease; Drug Evaluation; Humans; Leukocyte Count; Male; | 1990 |
New insights into the clinical profile of norfloxacin. Proceedings of a symposium held at the 6th Mediterranean Congress of Chemotherapy. Taormina, Italy, May 22-27, 1988.
Topics: Bacterial Infections; Humans; Norfloxacin | 1990 |
[Clinical evaluation of norfloxacin in children].
Topics: Administration, Oral; Adolescent; Age Factors; Bacterial Infections; Child; Child, Preschool; Drug E | 1990 |
[Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin].
Topics: Administration, Oral; Adolescent; Age Factors; Bacterial Infections; Child; Child, Preschool; Drug E | 1990 |
[Laboratory and clinical studies on norfloxacin in the pediatric field].
Topics: Adolescent; Age Factors; Bacteria; Bacterial Infections; Child; Child, Preschool; Drug Evaluation; D | 1990 |
[Laboratory and clinical studies on norfloxacin in pediatrics].
Topics: Adolescent; Age Factors; Bacteria; Bacterial Infections; Child; Child, Preschool; Drug Evaluation; D | 1990 |
[Laboratory and clinical studies of norfloxacin in pediatric field].
Topics: Adolescent; Age Factors; Bacteria; Bacterial Infections; Child; Child, Preschool; Drug Evaluation; D | 1990 |
[Clinical studies on norfloxacin in the field of pediatrics].
Topics: Adolescent; Age Factors; Bacterial Infections; Child; Drug Evaluation; Female; Humans; Male; Norflox | 1990 |
[Clinical evaluation of norfloxacin in pediatrics].
Topics: Administration, Oral; Adolescent; Age Factors; Bacteria; Bacterial Infections; Child; Child, Prescho | 1990 |
Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo.
Topics: Amikacin; Animals; Bacteria; Bacterial Infections; Enterococcus faecalis; Escherichia coli; Female; | 1989 |
Antibacterial activity of norfloxacin against 1700 relatively resistant clinical isolates.
Topics: Bacteria; Bacterial Infections; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Positive Bacteria; | 1989 |
In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Male; Mice; M | 1989 |
[The treatment of urinary tract infections with nolitsin].
Topics: Adult; Aged; Bacterial Infections; Drug Evaluation; Female; Gram-Negative Bacteria; Gram-Positive Ba | 1989 |
[Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs].
Topics: Adult; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Dose-Response Relations | 1989 |
Bacterial infections in liver transplant patients under selective decontamination with norfloxacin.
Topics: Adult; Bacterial Infections; Humans; Liver Transplantation; Norfloxacin; Postoperative Complications | 1989 |
Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens.
Topics: Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Humans; Norfloxacin | 1989 |
Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation.
Topics: Adolescent; Adult; Agranulocytosis; Bacterial Infections; Bone Marrow Transplantation; Child; Enviro | 1989 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquino | 1989 |
Comparative in vitro activity of ciprofloxacin against aerobic and anaerobic bacteria from clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Ciprofloxacin; | 1987 |
The efficacy of pefloxacin in comparison to gentamicin in the treatment of experimentally induced peritonitis in rats.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacteroides fragilis; Clo | 1986 |
Ciprofloxacin and norfloxacin--potent oral antiinfectives.
Topics: Administration, Oral; Bacterial Infections; Ciprofloxacin; Humans; Norfloxacin | 1989 |
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
Topics: Acinetobacter; Bacteria; Bacterial Infections; Ciprofloxacin; Citrobacter; Drug Resistance, Microbia | 1986 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
Activity of ciprofloxacin against resistant clinical isolates.
Topics: Bacteria; Bacterial Infections; Cefotaxime; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; | 1986 |
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Micr | 1986 |
A new method for the direct incorporation of antibiotic in prosthetic vascular grafts.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Blood Vessel Prosthesis; Cerium; Methods; Norf | 1987 |
[Clinical study of intestinal infections treated with norfloxacin].
Topics: Adult; Aged; Aged, 80 and over; Bacteria; Bacterial Infections; Drug Evaluation; Feces; Female; Gast | 1987 |
Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Bacterial Infections; Drug Evaluation; Drug Tolerance; Fem | 1986 |
Clinical uses of nalidixic acid analogues: the fluoroquinolones.
Topics: Administration, Oral; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Evaluation; D | 1986 |
Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.
Topics: Adolescent; Adult; Agranulocytosis; Bacterial Infections; Bone Marrow Transplantation; Female; Human | 1988 |
Emergence of resistance after therapy with antibiotics used alone or combined in a murine model.
Topics: Amikacin; Animals; Bacteria; Bacterial Infections; Ceftriaxone; Drug Resistance, Microbial; Drug The | 1986 |
Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient.
Topics: Administration, Oral; Agranulocytosis; Bacterial Infections; Digestive System; Gastrointestinal Dise | 1988 |
[Norfloxacin treatment of acute cystitis in the female and bacterial prostatitis].
Topics: Adult; Anti-Infective Agents, Urinary; Bacterial Infections; Cystitis; Female; Humans; Male; Microbi | 1985 |
[Norfloxacin sensitivity of bacterial pathogens of urinary tract infections].
Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Humans; Microbial Sensitivity Tests; Nalidixic | 1985 |
Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivi | 1988 |
Treatment of experimental cystitis in the rat with a single dose of fosfomycin trometamol.
Topics: Administration, Oral; Animals; Bacterial Infections; Cystitis; Drug Combinations; Fosfomycin; Norflo | 1988 |
Infections after experimental cadaver bone marrow transplantation in beagle dogs. Transplantations with and without selective gastrointestinal decontamination.
Topics: Amphotericin B; Animals; Bacterial Infections; Bone Marrow Transplantation; Digestive System; Dogs; | 1988 |
[Laboratory and clinical studies of norfloxacin in respiratory tract infections].
Topics: Adult; Aged; Bacteria; Bacterial Infections; Female; Humans; Male; Microbial Sensitivity Tests; Midd | 1988 |
Pefloxacin--a laboratory and clinical evaluation of a new quinolone. Based on papers presented at the 14th International Congress of Chemotherapy. Kyoto, Japan, June 1985.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Humans; Norfloxacin; Pefloxacin | 1986 |
Efficacy and safety of pefloxacin in the treatment of severe infections in patients hospitalized in intensive care units.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bronchopneumonia; Ch | 1986 |
[Pefloxacin: evaluation and clinical prospects].
Topics: Bacterial Infections; Evaluation Studies as Topic; Female; Humans; Lung Diseases; Male; Meningitis; | 1986 |
Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Ciprofloxacin; Enoxacin; Female; Humans; Ma | 1986 |
Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Hu | 1987 |
[Therapeutic contribution of the new quinolones].
Topics: Anti-Infective Agents; Bacterial Infections; Biotransformation; Chemical Phenomena; Chemistry; Cipro | 1987 |
In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Male; Mice; Microbial Sensit | 1987 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |
Compassionate use of norfloxacin.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections | 1987 |
Potential of topical norfloxacin therapy. Comparative in vitro activity against clinical ocular bacterial isolates.
Topics: Administration, Topical; Bacterial Infections; Eye Diseases; Humans; In Vitro Techniques; Microbial | 1987 |
In vitro antibacterial activity of E-3604, a new 6-fluoroquinolone, on clinical isolates.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Hydrogen-Ion Concen | 1987 |
Bactericidal and antineoplastic effect of combination of norfloxacin and adriamycin.
Topics: Animals; Bacteria; Bacterial Infections; Carcinoma, Ehrlich Tumor; Doxorubicin; Drug Interactions; D | 1987 |
Antimicrobial activity of norfloxacin in enteric and urinary tract infections: combined effect of norfloxacin with aminoglycosides, tetracycline and chloramphenicol.
Topics: Acinetobacter; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Chloramphenicol; Drug C | 1986 |
In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Microbial; Enoxacin | 1985 |
[Pefloxacin: clinical experience].
Topics: Acinetobacter Infections; Adult; Aged; Bacterial Infections; Enterobacteriaceae Infections; Enteroco | 1985 |